Physician profile
James O Nelson
NPI 1104826205
$916.48
in general payments reported to CMS, 2019-2025
22 companies · $34.21 in 2025
The $34.21 reported for 2025 was less than what a typical Physical Medicine & Rehabilitation provider received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $410 · 2020: $55.70 · 2021: $36.74 · 2022: $95.65 · 2023: $222 · 2024: $61.90 · 2025: $34.21.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $318.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $318.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $138.19 | 2023-2024 | |
| Tanabe Pharma America, INC. | $127.47 | 2019 | |
| Pfizer INC. | $87.86 | 2019 | |
| Nevro Corp. | $80.34 | 2019 | |
| Ferring Pharmaceuticals INC. | $64.82 | 2019-2023 | Euflexxa |
| Pacira Therapeutics, INC. | $57.89 | 2019-2020 | |
| Medtronic, INC. | $47.67 | 2023 | Aquamantys(Tm) |
| Biodelivery Sciences International, INC. | $29.06 | 2019-2020 | |
| Merz Pharmaceuticals, LLC | $28.78 | 2022 | |
| Amgen INC. | $28.60 | 2023 | Evenity, Prolia |
| Painteq LLC | $28.33 | 2023 | Painteq |
| Abbott Laboratories | $24.85 | 2023 | Eterna |
| Ultragenyx Pharmaceutical INC. | $21.93 | 2021 | |
| Daiichi Sankyo INC. | $21.14 | 2019 | |
| Nalu Medical, INC. | $19.58 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic USA, INC. | $17.40 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $17.20 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $17.01 | 2025 | Dysport |
| Allergan, INC. | $16.27 | 2019 | |
| Grt US Holding, INC. | $14.81 | 2021 | |
| Sanofi-Aventis U.S. LLC | $14.50 | 2019 | |
| Bioventus LLC | $12.78 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Nelson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.